Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas.

Date publication

juin 2024

Journal

Clinical genitourinary cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Pr LANG Hervé , Dr LINDNER Véronique , Pr ROY Catherine , Pr MALOUF Gabriel , Dr TRICARD Thibault , Pr OLLAND Anne , Dr BURGY Mickaël , Dr CAZZATO Roberto-Luigi

Tous les auteurs :
Moinard-Butot F, Oriel M, Tricard T, Cazzato RL, Pierard L, Gaillard V, Werle P, Lindner V, Martin S, Schuster C, Roy C, Burgy M, Anthony A, Bigot C, Boudier P, Fritsch A, Olland A, Malouf G, Lang H, Barthélémy P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38909529

Résumé

Immune checkpoint inhibitor (ICI)-based combinations have revolutionized the management of first-line metastatic renal cell carcinoma (mRCC) by improving patient survival. Large phase 3 randomized trials assessing ICI-based combinations have reported complete response (CR) rates of 10% to 18% in the first-line setting. However, there is a scarcity of data about the effect of treatment of residual disease regarding CR rates improvement.

Mots clés

Immune chekpoint inhibitor, Kidney cancer, Local treatment, Long-term outcomes, Response rate

Référence

Clin Genitourin Cancer. 2024 06 5;22(5):102134